Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 12.19
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers.
Data is available to registered users only
Target Price
The average target price of NVCR is 26 and suggests 110% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Data is available to registered users only
